ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl

ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl

Compare
Equity
Direct
Sector - Healthcare

NAV: ₹ 9.9 as on 06-12-2022

Fund Performance

Fund Performance

Return
1M
3M
6M
1Y
This Fund
-1.3%
6.6%
11.7%
0.9%
Benchmark
2.8%
4.3%
13.6%
9.2%
Category
-1.2%
5%
9%
-2.6%
About the Fund

ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is an equity fund. This fund was started on  11 November, 2021. The fund is managed by Rohan Korde, Pratibh Agarwal, Hetal Gada, Tanay Gabhawala. The fund could potentially beat inflation in the long-run.

Key parameters

1) ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl has a NAV of 9.8525 as on 06-12-2022.

2) ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl has 172 Cr worth of assets under management (AUM) as on 31-10-2022 and is less than category average.

3) The fund has an expense ratio 0.3 %.

Fund Overview

Expense ratio
Expense ratio
0.3%
Benchmark
Benchmark
S&P BSE Healthcare PR
AUM
AUM
₹172 Cr
Inception Date
Inception Date
11 November, 2021
Min Lumpsum/SIP
Min Lumpsum/SIP
₹5000/₹500
Exit Load
Exit Load
1%
Lock In
Lock In
No Lock-in
TurnOver
TurnOver
0%

Fund Distribution

  • Equity 98.4%
  • Debt & Cash 1.7%
Size breakup
Large cap
50.3%
Mid cap
26%
Small cap
18.9%

Sector Allocation

Oct'22

Sep'22

Aug'22

Health

94.3%

Basic Materials

3.2%

Financial Services

2.5%

Top Holdings

  • All
  • Equity
Total Holdings32
Equity Holdings32

What changed

in last one month
  • Scheme
  • Portfolio
AUM increased by 5.4 Cr in last 1M
Oct'22 return underperformed benchmark

Change in AUM

Oct'22
₹ 171.5 Cr
Sep'22
₹ 166.1 Cr
Aug'22
₹ 165.3 Cr

Fund Returns vs Benchmark

Oct'22
3.78%
5.37%
Sep'22
2.34%
-2.51%
Aug'22
0.03%
3.22%
Fund Return
Benchmark Return

Concentration Analysis

Fund
Oct'22
Oct'22
Aug'22
No of Holdings
32
30
31
Top 5 Company Concentration
50.8%
51.8%
49.9%
Company having highest exposure
Sun Pharmaceuticals Industries Ltd (21.6%)
Sun Pharmaceuticals Industries Ltd (21.3%)
Sun Pharmaceuticals Industries Ltd (20.2%)
No of Sectors
4
4
4
Top 5 Sectors Concentration
100%
100%
100%
Sector having highest exposure
Health (92.8%)
Health (94.3%)
Health (95.2%)

Fund Manager

Rohan Korde

Rohan Korde

Managing this fund since 11 November 2021

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ITI Long Term Equity Fund Direct Growth
14.59%
17.57%
ITI Arbitrage Fund Direct Growth
3.31%
3.73%
Pratibh Agarwal

Pratibh Agarwal

Managing this fund since 29 April 2022

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ITI Small Cap Fund Direct Growth
0%
32.27%
ITI Balanced Advantage Fund Direct Growth
0%
11.65%
ITI Multi Cap Fund Direct Growth
11.5%
20.79%
Hetal Gada

Hetal Gada

Managing this fund since 29 April 2022

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ITI Long Term Equity Fund Direct Growth
14.59%
17.57%
Tanay Gabhawala

Tanay Gabhawala

Managing this fund since 21 October 2022

Top funds managed

Scheme
Annualised Returns(3Y)
Category Returns(3Y)
ITI Small Cap Fund Direct Growth
0%
32.27%
ITI Balanced Advantage Fund Direct Growth
0%
11.65%
ITI Multi Cap Fund Direct Growth
11.5%
20.79%

AMC details

Address
Naman Midtown “A” Wing, 21st Floor, Senapati Bapat Marg, Elphinstone Road
Phone
022-66214999
Fund House
ITI Asset Management Limited

Fund Highlights

meter
pointer

Very High Risk

Investors understand that their principal will be at Very High Risk
Fund Allocations

Fund Allocations

This fund has an allocation of 98.35% in Equity, 0% in Debt and 1.65% in Cash related instruments
AUM size ₹172 Cr

AUM size ₹172 Cr

This fund has AUM of ₹172 Cr which is less than its category average of ₹ 1368 Cr
Expense Ratio 0.3%

Expense Ratio 0.3%

This fund has an expense ratio of 0.3% which is less than its category average expense ratio of 1.52%

Frequently Asked Questions

The current NAV of ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is 9.91.
Existing (Absolute + CAGR)
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
Absolute Returns
CAGR Returns
1 Month Returns
-1.3%
-1.3%
6 Month Returns
11.66%
11.66%
1 Year Returns
0.89%
0.89%
3 Years Returns
0%
0%
5 Years Returns
0%
0%
With INDmoney, the process of investing is very simple and involves zero commission.
  • Click Buy on the fund name.
  • Input the amount you are looking to invest.
  • Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
  • Select your bank account and proceed with Payment.
0.3 as on November 2022
172 Cr as on November 2022
Sun Pharmaceuticals Industries Ltd(21.62%),Cipla Ltd(8.13%),Lupin Ltd(8.13%),Torrent Pharmaceuticals Ltd(6.69%),Dr Reddy's Laboratories Ltd(6.2%) as on November 2022
Health(92.79%),Basic Materials(3.13%),Financial Services(2.44%) as on November 2022
The alpha ratio for the ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Alpha 1 Year
Alpha 3 Years
Alpha 5 Years
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
4.16
-
-
As on month end.
The alpha for ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Beta 1 Year
Beta 3 Years
Beta 5 Years
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
0.91
-
-
As on month end.
The Beta for ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Sharpe Ratio 1 Year
Sharpe Ratio 3 Years
Sharpe Ratio 5 Years
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
-0.18
-
-
As on month end.
The sharpe ratio for ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name
Standard Deviation 1 Year
Standard Deviation 3 Years
Standard Deviation 5 Years
ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
15.15
-
-
As on month end.
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Rohan Korde,Pratibh Agarwal,Hetal Gada,Tanay Gabhawala are the fund managers of ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl
The Exit load of ITI Pharma and Healthcare Fund Direct Payout Inc Dist cum Cap Wdrl is 1%

Mutual Fund execution provided by

Technology facilitation Services provided by Finzoom Investment Advisors Pvt. Ltd. - Advisory unit. SEBI Registered Investment Advisor: INA100012190 | BASL Registration No. 1154 | BSE StarMF Platform code: 24801

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme related documents carefully. Past performance is not indicative of future returns.